Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | PGR | P06401 | 3/20 | 0.74 |
| ▸ | AR | P10275 | 3/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | STS | P08842 | 2/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.74 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol SCHEMBL17419455 | 1.00 | ESR1 (0.74) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL26659977 | 1.00 | ESR1 (0.74) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL547939 | 1.00 | ESR1 (0.74) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL27642993 | 1.00 | ESR1 (0.74) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL26659961 | 0.99 | ESR1 (0.75) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL8001333 | 0.96 | ESR1 (0.77) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL7638916 | 0.96 | ESR1 (0.77) | ESR1LMNAMAPTESR2KMT2A | |
| Alfatradiol SCHEMBL22092636 | 0.96 | ESR1 (0.77) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL40565 | 0.96 | ESR1 (0.77) | ESR1LMNAMAPTESR2KMT2A | |
| Estradiol SCHEMBL7186616 | 0.96 | ESR1 (0.77) | ESR1LMNAMAPTESR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| WO-2023223235-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | PURNA PHARMACEUTICALS NV (BE) | 2023-11-23 | — | — | WO | disclosed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| US-6265147-B1 | DETECTING MODULATORS OF BRAIN ACTIVITY; MIX MODULATOR WITH RECEPTORS AND DETECT ACTIVATION OF RECEPTORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2001-07-24 | — | — | US | disclosed |
| WO-2001039780-A1 | ACTIVATION OF NOVEL ESTROGEN RECEPTOR SUPPORTS NEURONAL VIABILITY AND FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | ESR1 188/4885LMNA 796/4885MAPT 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.